FIGURE 4.

Atrophy analysis, 6–24 months, from 184 patients treated with cladribine 3.5 mg/kg and 186 patients treated with placebo. Brain volume loss from 6 to 24 months was reduced in patients treated with cladribine tablets 3.5 mg/kg body weight, with a significant difference in percentage volume change between cladribine and placebo for grey matter (GM) only. The ∆% change in the treated group and the standard errors are indicated in the figure. Abbreviations: CladT3.5, cladribine tablets 3.5 mg/kg; PVC, percentage volume change; WM, white matter